ARCT241220C20000
- 0.03
- -0.02-40.00%
Arcturus Therapeutics Newsroom
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Express News | Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight
Arcturus Therapeutics Analyst Ratings
This Arcturus Therapeutics Holdings Insider Reduced Their Stake By 18%
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers
Positive Outlook for Arcturus Therapeutics Driven by Innovative Vaccine Kostaive
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $74
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Express News | Meiji Seika Pharma Announces Investment in Arcalis, Inc.
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Arcturus Therapeutics: Overcoming Challenges and Poised for European Expansion
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate
Arcturus Therapeutics Receives FDA Clearance to Begin H5N1 Vaccine Trial
Express News | Arcturus Therapeutics Holdings Inc - Study to Enroll Approximately 200 Healthy Adults in U.S.
Express News | Arcturus Therapeutics Receives Clearance From FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics: Strong Buy Rating Backed by Promising Kostaive Sales and Promising Pipeline Developments